The current advent of molecular technologies together with a multidisciplinary interplay of several fields led to the development of in vitro diagnostics (IVD), which concentrates on the detection of pathogenic events at the nucleic acid and protein level. Various promising technologies and diagnostic applications are currently paving the way for the rapid diagnosis of disease. Armed with rich experience in IVD and an excellent technical team, Creative Biolabs provides a comprehensive set of gene diagnosis and analysis services for worldwide clients.
Currently, polymerase chain reaction (PCR) technology is considered the gold standard by many across the diagnostic community, since it can theoretically identify and detect a target with a single copy present in the sample. PCR technology is also rapid and can be performed in hours to minutes compared to serology and pathogen culture and isolation, which is labor intensive and can take long time to produce a result. Serology or culture may not provide the same level of sensitivity as PCR. Therefore, the risk of false negatives increases in critical testing scenarios where organisms or viruses may be difficult to grow or detect an immune response to.
Classical molecular techniques like normal PCR and blotting although played satisfactory roles in diagnosis. However, currently, molecular techniques may detect more precisely and specifically without consuming much time. A wide range of molecular based tests is available to evaluate DNA difference and changes in gene through real-time PCR, fluorescent in situ hybridization (FISH), enzymatic-based methods, electrophoretic-based techniques, solid phase-based techniques/hybridization or blotting techniques, microarrays, sequencing, CRISPR-based method, and so forth.
Fig.1 CRISPR-Cas13a can quantitatively detect SARS-CoV-2 RNA without pre-amplification. (Katalani, 2020)
Better diagnostic tests have led to the development of more targeted therapies, further developing the scope for better healthcare facilities. The real-time PCR-based platform holds great promise in replacing conventional laboratory-based testing for future point-of-care (POC) testing. With advancements in automation, integration of specimen preparation with target identification, and miniaturization, it will become much easier to bring analyses near the bedside to be done by less-trained personnel. Creative Biolabs, along with global partners, supports the development of gene diagnostic to strengthen IVD research. Creative Biolabs provides specific technical assistance in the following areas:
For Research Use Only.